查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球处方皮肤病治疗市场-2022-2029
市场调查报告书
商品编码
1140723

全球处方皮肤病治疗市场-2022-2029

Global Prescription Dermatological Drugs Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

2021 年皮肤科处方药市场价值 258.7 亿美元。预计在预测期内（2022-2029 年）将以 6.20% 的复合年增长率增长。

皮肤病学包括对皮肤、脂肪、头髮、指甲、口腔和生殖器膜的正常和紊乱、疾病、癌症、美容和老化状况的调查、研究和诊断。痤疮、皮炎、湿疹、牛皮癣、真菌感染、疣、对感冒和皮肤癌的敏感性是皮肤科的主要适应症。大约每 6 个人中就有 1 人会因为皮肤问题去看 GP。

规定的皮肤科药物包括皮肤相关疾病、痤疮和生殖器疱疹等皮肤问题、皮肤伤口、皮肤和头皮、头髮和指甲、皮肤和脂肪、头髮、指甲、口腔等美容问题。治疗老化现象，例如市场主要由各种皮肤病处方药的供应所主导，例如免疫疗法、局部用药、全身用药和其他药物。

市场动态

皮肤病的增加推动市场增长

随着皮肤病的增加，对作为处方药的皮肤科处方药的需求正在增加，这推动了市场。根据美国卫生计量研究所进行的全球疾病负担 (GBD) 研究，皮肤病占全球疾病负担的 1.79%。皮炎、牛皮癣、蜂窝组织炎、脓皮病、疥疮、真菌性皮肤病、病毒性皮肤病、寻常痤疮、斑秃、瘙痒、荨麻疹、褥疮、皮肤恶性黑色素瘤、角质形成细胞癌是世界范围内最常见的皮肤病。根据世界卫生组织 (WHO) 的数据，已发现各国银屑病的患病率在 0.09% 至 11.4% 之间。牛皮癣的患病率在发达国家从 1.5% 到 5% 不等。特应性皮炎 (AD) 是最常见的慢性或复发性炎症性皮肤病，影响全球 15-20% 的儿童和 1-3% 的成年人。根据美国国立卫生研究院 (NIH) 的数据，痤疮是世界上第八大最常见的疾病，影响着世界人口的 9.4%。

皮肤科处方药贷款和资金的增加推动市场增长

几家公共和私营公司也在增加资金和资金，用于开发处方皮肤病学治疗。例如，2020 年 10 月，Sirnaomics 获得了 1.05 亿美元的 D 轮融资。这笔资金用于推进 RNAi 疗法的研发（R&D）过程，以治疗皮肤癌、纤维化疾病、代谢疾病和病毒感染等各种适应症。 2019 年 1 月，Vyome Therapeutics Inc 完成了 2200 万美元的融资。该公司利用这笔资金将其先导分子 VB 1953 推进到治疗中度至重度痤疮及其业务的 II 期试验。皮肤科相关项目由多个机构和组织资助。美国国立卫生研究院向 2015 年至 2019 年间在 171 个机构开展的 1764 个皮肤病学相关项目提供了 5.542 亿美元。 NIH 对皮肤病学相关项目的资助从 2015 年的 1.044 亿美元增加到 2019 年的 1.199 亿美元，增长了 14.7%。

与处方皮肤科药物使用相关的副作用阻碍市场增长

市场受到与使用处方皮肤病药物相关的副作用的阻碍。副作用包括噁心、腹痛、气短、脚踝和足部肿胀、高脂血症、血尿、背痛、发热、黄斑皮疹、头痛和高血压，并且可能在患者中观察到。使用处方皮肤病药物会增加发生真菌、细菌和病毒感染的机会。可能会出现严重的过敏反应，例如荨麻疹、呼吸困难、面部、眼睛、嘴唇和嘴巴肿胀。

COVID-19 影响分析

由于感染 COVID-19 的人数不断增加，对处方皮肤药的需求不断增加，全球处方皮肤药市场正呈现正增长。越来越多地采用处方皮肤科药物来治疗 COVID-19 感染者的皮肤状况。根据 Esther E Freeman 等人，2020 年，大约 0.2% 至 20.4% 的 COVID-19 患者有皮肤表现。黄斑丘疹、假性紫癜、荨麻疹、单形播散性滤泡性病变、肢端水疱性化脓性病变、青斑或坏死是 COVID-19 感染者最常见的皮肤表现。根据由美国皮肤病学会和国际皮肤病学会联合会联合运营的 COVID-19 登记，在 171 名经实验室确认的皮肤表现的 COVID-19 患者中，约 22% 患有髋臼，18% 患有冻疮样肢端病变，荨麻疹 16%，黄斑红斑 13%，滤泡性皮疹 11%，乳头状鳞状细胞疹 9.9%，网状紫癜 6.4%。根据 Sanchez-Arraez 等人的 2020 年，在成人和儿童中观察到 COVID-19 的皮肤表现中，约 30% 为急性红斑，20% 为乳头炎，35% 为黄斑紫癜，15% 为混合型。 .皮肤科处方药，如生物製剂、免疫调节剂和免疫抑製剂，在治疗 COVID-19 引起的皮肤症状方面越来越受欢迎。

流行病学

根据美国癌症协会的数据，预计 2020 年美国将出现大约 100,350 例黑色素瘤病例。预计到 2020 年将有大约 6,850 人死于黑色素瘤。根据美国斑秃协会的数据，美国约有 680 万人患有或可能患上斑秃。根据美国脱髮协会的数据，大约 95% 的男性脱髮是由于男性型脱髮。在中欧和东欧国家，特应性皮炎的患病率已被证实为 7.3%。在法国，成人特应性皮炎的患病率为 8%。多种因素会增加患特应性皮炎的风险，包括城市环境、较高的社会经济地位和家族史。据估计，寻常痤疮会影响美国 80% 的人在其一生中。大约 20% 的严重痤疮患者最终会留下永久性的身体和心理疤痕。

市场细分

银屑病药物有望占据处方皮肤科市场的最大份额

按产品类型分为痤疮/红斑痤疮治疗、抗衰老治疗、皮炎/皮脂溢治疗、脱髮/脱髮治疗、牛皮癣治疗、皮肤癌治疗等。银屑病药物预计将占处方皮肤病学市场的最大份额，因为银屑病患病率的增加正在推动对银屑病药物的需求。根据世界卫生组织 (WHO) 的数据，牛皮癣的患病率从 0.09% 到 11.4% 不等，并且发生在许多不同的国家。牛皮癣的患病率在发达国家从 1.5% 到 5% 不等。市场主要由皮质类固醇、钙调神经磷酸□抑製剂、□林、甲氨蝶呤、环孢素、生物製剂和其他治疗银屑病的药物的供应主导。生物製剂可以帮助改善牛皮癣的症状和体征。一些生物製剂，如依那西普 (Enbrel)、英夫利昔单抗 (Remicade)、阿达木单抗 (Humira)、优特克单抗 (Stelara)、苏金单抗 (Cosentyx) 和伊塞克珠单抗 (Taltz)，对一线治疗无反应，中度至批准用于治疗严重的牛皮癣。据报导，阿达木单抗（修美乐）在临床试验中显示，在短短 4 个月内，中度至重度斑块状银屑病患者的皮肤癒合率为 75% 甚至 90%。

按销售渠道来看，预测期内医院药房的销售额预计将显着增长

市场按分销渠道分为医院药房、零售药房、在线药房等。由于医院药房中高成本皮肤科处方药的高可用性，预计医院细分市场增长最快。随着住院人数的增加，用于预防、治疗和管理慢性皮肤病的皮肤科药物的使用也在增加。

区域分析

北美占处方药市场的最大份额。

由于皮肤和其他疾病的高发率，北美地区在 2021 年占全球处方皮肤病学市场的最大市场份额。根据皮肤癌基金会的数据，美国每天约有 9,500 人被诊断出患有皮肤癌。到 70 岁时，至少有五分之一的美国人会患上皮肤癌。基底细胞癌 (BCC) 是最常见的皮肤癌，在美国每年诊断出 430 万人。鳞状细胞癌 (SCC) 影响超过 100 万人。根据美国皮肤病学会 (AAD) 的数据，美国每年约有 5000 万美国人患有痤疮。根据美国国家生物技术信息中心的数据，特应性皮炎影响全球约 20% 的婴儿和 3% 的成人。

由于皮肤科处方药的高渗透率，美国的市场份额最高。有几个市场先驱正在开发处方皮肤药物。此外，几家公司正在与公司合作，以提高对处方皮肤病治疗的认识。例如，辉瑞公司于2022年1月14日开发的成人用CIBINQO（abrocitinib）获美国食品药品监督管理局批准用于治疗成人难治性中度至重度特应性皮炎（AD）的增加。在这些受影响的个体中，大约 40% 的成年人出现中度至重度症状。预计在预测期内，医疗设施和基础设施建设方面的重大医疗支出也将对市场产生积极影响。

预计亚太地区将在预测期内以最快的复合年增长率增长

由于大量患有皮肤病且医疗需求未得到满足的人群，导致皮肤科处方药的高渗透率，估计亚太地区是全球市场增长率最高的地区。用于治疗痤疮的局部皮肤病药物的使用正在增加，包括抗炎剂、抗感染剂、局部麻醉剂、清洁剂和软膏。此外，生物製剂越来越多地用于治疗中度至重度皮肤病，例如牛皮癣。对美丽的日益增长的认识和对肥胖的担忧预计将对市场产生积极影响。

皮肤科领域的处方药临床试验数量正在增加。医用皮肤科药物的开发进展迅速。公共机构和私营公司在开发处方皮肤药方面的研发投入和资金有所增加。医疗旅游的扩展，以可承受的价格提供医疗服务，预计将对市场产生积极影响。中国、日本、澳大利亚和印度等国家可能会增加获得皮肤护理治疗的机会，从而增加对处方皮肤药物的需求。此外，预计国民收入和购买力的提高将在预测期内刺激市场增长。

竞争格局

处方皮肤病学市场是一个分散的市场，拥有大量公司。强生公司、默克公司、拜耳公司、辉瑞公司、F. Hoffmann-La Roche、艾尔建、艾伯维公司、安斯泰来製药公司、Biofrontera 公司、百时美施贵宝、德米拉公司、葛兰素史克公司、迈兰公司N.V.等是一家市场占有率很大的大公司。公司正在采取多种增长战略，例如产品发布、收购、合併、合作伙伴关係和许可，以增加其市场占有率。例如：

合併与合作。

2019 年 11 月，Excelra 与专门从事皮肤病学的製药公司 Maruho 建立了药物再利用合作伙伴关係。根据协议条款，Excelra 将与 Maruho 的研究团队合作，发现和开发皮肤病学的新治疗假设。该合作伙伴关係还将使 Maruho 能够访问 Excelra 的药物再利用平台（ GRIP ），该平台由再利用数据库、再利用算法、分析工具和可视化引擎组成。

产品发布和批准

2019 年 6 月，博世健康公司及其皮肤科业务 Ortho Dematronics 宣布在美国推出 DUOBRII（丙酸卤倍他索和他扎罗汀）乳液，0.01%/0.045%。 DUOBRII 是世界上第一个将低浓度卤代倍他索丙酸酯和他扎罗汀在专利乳液载体中的单一局部配方配方。

2019 年 2 月，Evolus, Inc. 被美国食品药品监督管理局 (FDA) 批准为“暂时改善成人中与皱眉肌和/或前眉肌活动相关的中度至重度砾石线的外观。”我们已获得 Jubault 的批准，用于

收购

2020 年 2 月，礼来公司收购了美国的 Dermira, Inc.。此次收购提供了一种旨在对 IL-13 具有高亲和力的药物，该药物正在 III 期临床开发计划中进行评估，用于治疗青少年和 12 岁及以上成人的中度至重度特应性皮炎。免疫学管道增加了一种新的研究性单克隆抗体lebrikizumab。根据协议条款，礼来公司以每股 18.75 美元的价格将 Dermira 的所有已发行普通股换成现金。

2020 年 8 月 19 日，强生公司宣布了一项收购 Momenta Pharmaceuticals, Inc. 的协议。约65亿美元的全现金交易。此次收购为强生旗下杨森製药公司扩大其在免疫介导疾病领域的领导地位提供了机会。

2019 年 7 月，LEO Pharma 收购了拜耳的全球处方皮肤科业务。此次收购将扩大公司的治疗领域并加强其全球影响力。根据协议条款，LEO Pharma 将获得除阿富汗和巴基斯坦以外的全球产品权利。它还包括位于意大利 Segrate 的生产设施。

建立伙伴关係。

2020 年 6 月，人工智能药物发现公司 Repurpose.AI 与全球医学皮肤病学领导者 LEO Pharma A/S 合作，共同发现和验证针对炎症和皮肤病学适应症的治疗药物。我们签署了创新合作伙伴关係.该合作伙伴关係将利用 Repurpose AI 的 ActivPred AI。

使用药物发现平台（与药物、靶点和疾病无关的数字化学引擎），我们旨在发现炎症性皮肤病的候选药物。

内容

第1章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

  • 按产品类型划分的市场细分
  • 按管理途径划分的市场细分
  • 按分销渠道划分的市场细分
  • 按地区划分的市场细分

第 4 章市场动态

  • 市场影响因素
    • 驱动程序
      • 皮肤病增加
      • 增加筹款和贷款
    • 限制因素
      • 处方皮肤科药物的副作用
    • 商机
    • 影响分析

第5章行业分析

  • 波特五力分析
  • 流行病学
  • 管道分析
  • 供应链分析
  • 定价分析
  • 法律法规分析
  • 保险报销分析
  • 未满足的需求分析

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按产品类型

  • 痤疮和酒渣鼻治疗
  • 抗衰老药
  • 皮炎和脂溢性药物
  • 脱髮和拔毛癖的治疗
  • 牛皮癣的治疗
  • 皮肤癌药物
  • 其他

第 8 章给药途径

  • 外部代理
  • 口语
  • 家长代理
  • 其他

第 9 章按分销渠道

  • 医院药房
  • 零售药房
  • 在线药店
  • 其他

第 10 章按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 11 章竞争格局

  • 竞争场景
  • 市场情况/份额分析
  • 併购分析

第 12 章公司简介

  • 强生公司
    • 公司概况
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • Merck & Co., Inc.
  • Bayer AG
  • Sanofi
  • Pfizer
  • F. Hoffmann-La Roche
  • Allergan
  • Valeant Pharmaceuticals
  • Pharmaderm Pharmaceuticals
  • Abbvie, Inc
  • Almirall, S.A.
  • Astellas Pharma, Inc
  • Biofrontera AG
  • Bristol-Myers Squibb
  • Cipher Pharmaceuticals
  • Dermira, Inc.
  • Glaxosmithkline Plc
  • Mylan N.V.（LIST NOT EXHAUSTIVE）

第13章 DataM

简介目录
Product Code: DMPH2796

Market Overview

Prescription Dermatological Drugs Market was valued at USD 25870 million in 2021. It is forecasted to reach USD YY million by 2029, growing at a CAGR of 6.20% during the forecast period (2022-2029).

Dermatology includes the study, research, and diagnosis of normal and disorders, diseases, cancers, cosmetic and ageing conditions of the skin, fat, hair, nails and oral and genital membranes. acne, dermatitis, eczema, psoriasis, fungal infections, warts, cold sore, and skin cancer are the most common dermatology indications. Approximately, one in six of the people visit the general practitioners for the skin disorders.

Prescription dermatological drugs are used for the treatment of the skin related diseases, skin problems such as acne, genital herpes, skin wounds, cosmetic problems of the skin, scalp, hair, & nails, and ageing conditions of the skin, fat, hair, nails, oral and other conditions. The market is dominated by the availability of the various prescription dermatological drugs such as immunotherapy, topical medications, systemic medications, and other medications.

Market Dynamics

Rising Prevalence of Skin Disorders is Driving the Growth of the Market

The market is driven by the increasing demand for the Prescription Dermatological Drugs with the increasing prevalence of the skin disorders. According to Global Burden of Disease (GBD) study conducted by the Institutes of Health Metrics, the skin conditions accounts for the 1.79% to the total global burden of disease. Dermatitis, psoriasis, cellulitis, pyoderma, scabies, fungal skin diseases, viral skin diseases, acne vulgaris, alopecia areata, pruritus, urticarial, decubitus ulcer, malignant skin melanoma, and keratinocyte carcinoma are the most frequent skin conditions across the globe. According to the World Health Organization (WHO), the prevalence of psoriasis ranges from the 0.09% and 11.4% in the various countries. The prevalence of the psoriasis ranges from the 1.5 and 5% in the most developed countries. Atopic dermatitis (AD) is the most common chronic or recurrent inflammatory skin disease that affects 15-20% of children and 1-3% of adults worldwide. As per the National Institute of Health (NIH), acne is the eighth most prevalent disease worldwide that affects 9.4% of the global population.

Rising Financing & Funding for Prescription Dermatological Drugs is Boosting the Market Growth

Several public & private companies are also raising the financing and funding for development of prescription dermatological drugs. For instance, in October 2020, Sirnaomics had grabbed a $105 million series D round. This funding was used for the advancing the research & development (R&D) process for its RNAi therapeutics for the treatment of various indications such as skin cancer, fibrosis diseases, metabolic diseases and viral infections. In January 2019, Vyome Therapeutics Inc, had closed the $22 million financing. The company had used the funding for the advancing its lead molecule i.e., VB 1953 to phase II studies for treatment of moderate to severe acne and for operations. Several institutes & organizations are raising the funding for the dermatology-related projects. National Institute of Health had awarded the USD 554.2 million to 1764 dermatology-related projects conducted at 171 institutions during the year 2015 to 2019. The NIH funding for dermatology-related projects had witness the increase at a rate of 14.7% from the USD 104.4 million in 2015 to USD 119.9 in 2019.

Adverse Effects Associated with the use of prescription dermatological drugs is Hampering the Market Growth

The market is hindered by the adverse effects associated with the use of the prescription dermatological drugs. Several adverse effects include nausea, abdominal pain, shortness of breath, swelling of ankles or feet, hyperlipidemia, hyperpigmentation hematuria, back pain, fever, maculopapular rash, headache, hypertension, and others are observed among the patients. The use of the prescription dermatological drugs increases the chances of developing the fungal, bacterial, and viral infection. Serious allergic reaction such as hives, trouble breathing, and swelling of your face, eyes, lips, or mouth are observed among the patients.

COVID-19 Impact Analysis

The global prescription dermatological drugs market has witnessed the positive market growth due to increasing demand for the prescription dermatological drugs with the increasing number of people suffering from the COVID-19. There is increasing adoption of the prescription dermatological drugs for treating the cutaneous manifestations observed among the patients with COVID-19 infection. According to the Esther E Freeman et.al., 2020, approximately 0.2% to 20.4% of COVID-19 patients had cutaneous manifestations. Maculopapular eruption, pseudo-chilblain lesions, urticaria, monomorphic disseminated vesicular lesions, acral vesicularpustulous lesions, and livedo or necrosis are the most common cutaneous manifestations observed among the patients with COVID-19 infection. According to the American Academy of Dermatology's COVID-19 Registry, a collaboration between the American Academy of Dermatology and the International League of Dermatologic Societies, out of 171 laboratory-confirmed COVID-19 patients with cutaneous manifestations, around 22% of patients had morbilliform rash, 18% of patients had pernio-like acral lesions, 16% of patients had urticaria, 13% of patients had macular erythema, 11% of patients had vesicular eruption, 9.9% of patients had papulosquamous eruption, and 6.4% of patients had retiform purpura. As per the Sanchez-Arraez et al 2020, approximately, 30% of acral erythema, 20% of dactylitis, 35% of purpuric maculopapules, and 15% of mixed pattern were observed among the COVID-19 adults and children with cutaneous manifestations. There is growing penetration of the prescription dermatological drugs such as biologics, immunomodulators and immunosuppressants for the treatment of the cutaneous manifestations with COVID-19.

Epidemiology

According to the American Cancer Society, approximately 100,350 number incidence cases of melanoma are expected to observed in the United States in 2020. Around 6,850 number of people are expected to died due to melanoma in 2020. According to the National Alopecia Areata, approximately, 6.8 million people have or would develop the Alopecia Areata in the United States. As per the American Hair Loss Association, approximately 95% of the hair loss occurred due to the androgenetic alopecia among the men. The prevalence of atopic dermatitis was observed to be 7.3% in central and eastern european countries. The prevalence of atopic dermatitis was 8% among the adults in France. Various factors such as urban environment, higher socioeconomic status, family history and other factors increase the risk of developing atopic dermatitis. Acne vulgaris affects 80% of people during their lives in the United States. Around 20% of people with severe acne has resulted in permanent physical and mental scarring.

Market Segment Analysis

Psoriasis Drugs segment is expected to hold the largest share in the Prescription Dermatological Drugs market

By Product Type, the market is classified as the acne & rosacea drugs, anti-aging drugs, dermatitis & seborrhea drugs, hair loss & hair removal drugs, psoriasis drugs, skin cancer drugs, and others. The psoriasis drugs segment is anticipated to hold the largest share in the prescription dermatological drugs market due to the higher demand of the psoriasis drugs with the increasing prevalence of the psoriasis. According to the World Health Organization (WHO), the prevalence of psoriasis ranges from the 0.09% and 11.4% in the various countries. The prevalence of the psoriasis ranges from the 1.5 and 5% in the most developed countries. The market is dominated by the availability of the corticosteroids, calcineurin inhibitors, anthralin, methotrexate, cyclosporine, biologics and other drug for the treatment of the psoriasis. Biologics are effective improving the signs and symptoms of psoriasis. Several biologics such as etanercept (Enbrel), infliximab (Remicade), adalimumab (Humira), ustekinumab (Stelara), secukinumab (Cosentyx) and ixekizumab (Taltz) have been approved for the treatment of the moderate to severe psoriasis who are not responding to the first line of therapies. Clinical studies have demonstrated that the use of the adalimumab (Humira) among the patients with moderate to severe chronic plaque psoriasis had resulted in 75% and even 90% skin clearance in just 4 months.

By Distribution Channel, Hospital Pharmacies Segment is Expected to Witness a High Growth Over the Forecast Period

The market is classified based on the distribution channel as the hospital pharmacies, retail pharmacies, online pharmacies and others. The hospital pharmacies is segmented to have the highest market growth due to the higher availability of the prescription dermatological drugs with the high cost in the hospital pharmacies. There is increasing usage of the prescription dermatological drugs for the prevention, treatment, and management of chronic dermatological disorders with the increasing in the number of the admitted to the hospitals.

Geographical Analysis

North America region holds the largest market share global Prescription Dermatological Drugs market

North America region is dominating the global prescription dermatological drugs market accounted for the largest market share in 2021 owing to the high prevalence of the skin disorders and other diseases. According to the Skin Cancer Foundation, every day, around 9,500 people are diagnosed with skin cancer in the United States. At least one in five Americans develop skin cancer by 70. Basal cell carcinoma (BCC) is the most common form of skin cancer with 4.3 million cases diagnosed in the United States annually. More than one million people suffer from Squamous cell carcinoma (SCC). According to the American Academy of Dermatology Association (AAD), every year acne affects around 50 million Americans in the United States. As per the National Center for Biotechnology Information, around 20% of infants & children and 3% of adults had atopic dermatitis worldwide.

The United States accounts for the highest market share due to the higher penetration of the prescription dermatological drugs. There is presence of the several market players developing prescription dermatological drugs. Several companies are entering into the collaboration with the companies for raising the awareness regarding the skin disorders being treated by using the prescription dermatological drugs. For instance, on 14th January 2022, Pfizer developed CIBINQO (abrocitinib) for adults, approved by the United States Food and Drug Administration for treating adults with refractory conditions moderate-to-severe atopic dermatitis (AD). Out of these affected adults, around 40% of adults have moderate or severe symptoms. The high healthcare expenditure for improving the healthcare facilities and infrastructure shall have the positive impact on the market over the forecasted period.

Asia-Pacific region is expected to grow at the fastest CAGR during the forecast period

Asia-Pacific region is estimated to be the fastest-growing region in the global prescription dermatological drugs market owing to the increasing penetration of the prescription dermatological drugs as the large proportion of the population is suffering from the dermatology disorders with unmet medical needs. There is higher usage of the topical dermatological drugs such as anti-inflammatory agents, anti-infective, local anesthetics, cleansers, and emollients for treating acne. There is increasing adoption of the biologics for the treatment of moderate to severe dermatological diseases including the psoriasis, and other disorders. The growing beauty consciousness and obesity concerns shall have a positive impact on the market.

There is increase in the number of the clinical trials being conducted for evaluating the prescription dermatological drugs. There are rapid advancements in the development of the prescription dermatological drugs. There is rising investment and funding in the research and development activities by the several public and private market players to develop the prescription dermatological drugs. The growing medical tourism due to the availability of the affordable treatment options shall have positive impact on the market. There is improving access to skin care treatments in the several countries such as China, Japan, Australia and India shall increase the demand for the prescription dermatological drugs. The growing domestic income and purchasing power of people shall stimulate the market growth over the forecasted period.

Competitive Landscape:

The prescription dermatological drugs market studied is a fragmented market with the presence of large number of market players. Johnson & Johnson Inc., Merck & Co., Inc., Bayer AG, Pfizer, F. Hoffmann-La Roche, Allergan, Abbvie, Inc, Astellas Pharma, Inc, Biofrontera AG, Bristol-Myers Squibb, Dermira, Inc., Glaxosmithkline Plc, and Mylan N.V. are the major market players with the significant market share. Companies are adopting several growth strategies such as product launches, acquisitions, mergers, collaborations, and licensing for increasing their market presence. For instance,

Mergers & Collaborations:

In November 2019, Excelra had entered into the drug repurposing collaboration with Maruho, a pharmaceutical company specialising in Dermatology. Under the terms of agreement, Excelra would jointly work with Maruho's research team to discover and develop novel therapeutic hypotheses in Dermatology. This collaboration would also provide Maruho an access to Excelra's proprietary Drug Repurposing Platform (GRIP) that comprises of proprietary Repurposing Database, Repurposing Algorithms, Analytics tools and visualization engine.

Product Launch & Approvals:

In June 2019, Bausch Health Companies Inc. and its dermatology business, Ortho Dermatologics had launched the DUOBRII (halobetasol propionate and tazarotene) Lotion, 0.01%/0.045% in the United States. The DUOBRII formulation comprised of the unique lotion vehicle with low concentrations of halobetasol propionate and tazarotene, into a single, first-of-its-kind topical treatment.

In February 2019, Evolus, Inc had received the approval for the Jeuveau from the United States Food and Drug Administration (FDA) for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adults.

Acquisition:

In February 2020, Eli Lilly and Company had acquired the Dermira, Inc. This acquisition had expanded the company's immunology pipeline with the addition of lebrikizumab, a novel, investigational, monoclonal antibody designed to bind IL-13 with high affinity that is being evaluated in a Phase III clinical development program for the treatment of moderate-to-severe atopic dermatitis in adolescent and adult patients, ages 12 years and older. Under the terms of agreement, Eli Lilly and Company had offered all outstanding shares of common stock of Dermira, at a price of $18.75 per share in cash.

On 19th August 2020, Johnson & Johnson announced it had agreed to acquire Momenta Pharmaceuticals, Inc. The acquisition deal with all cash transactions for approximately $6.5 billion. This acquisition Provides an opportunity for the Janssen Pharmaceutical Companies of Johnson & Johnson to broaden its leadership in immune-mediated diseases.

In July 2019, LEO Pharma had acquired the Bayer's global prescription dermatology business. This acquisition would help the company to expand its therapeutic areas and bolster a global footprint. Under the terms of agreement, LEO Pharma would gain global product rights, except in Afghanistan and Pakistan. It also includes the production facility in Segrate, Italy.

Partnership:

In June 2020, Repurpose.AI, an artificial intelligence drug discovery company had entered into the open innovation partnership with LEO Pharma A/S, a global leader in medical dermatology, to discover and validate drugs to treat inflammatory and dermatology indications. This partnership would leverage Repurpose AI's ActivPred AI

Drug Discovery Platform, an unbiased drug, target and disease agnostic digital chemistry engine, to discover drug candidates for inflammatory skin diseases

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Product Type
  • 3.2. Market Snippet by Route of Administration
  • 3.3. Market Snippet by Distribution Channel
  • 3.4. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Prevalence of Skin Disorders
      • 4.1.1.2. Rising Funding & Financing
      • 4.1.1.3. XX
    • 4.1.2. Restraints
      • 4.1.2.1. Adverse Effects of Prescription Dermatological Drugs
      • 4.1.2.2. XX
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Epidemiology
  • 5.3. Pipeline Analysis
  • 5.4. Supply Chain Analysis
  • 5.5. Pricing Analysis
  • 5.6. Regulatory Analysis
  • 5.7. Reimbursement Analysis
  • 5.8. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type Segment
  • 7.3. Market Attractiveness Index, By Product Type Segment
    • 7.3.1. Acne & Rosacea Drugs*
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. Anti-Aging Drugs
    • 7.3.3. Dermatitis & Seborrhea Drugs
    • 7.3.4. Hair Loss & Hair Removal Drugs
    • 7.3.5. Psoriasis Drugs
    • 7.3.6. Skin Cancer Drugs
    • 7.3.7. Others

8. By Route of Administration

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration Segment
  • 8.3. Market Attractiveness Index, By Route of Administration Segment
    • 8.3.1. Topical*
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.3.2. Oral
    • 8.3.3. Parenteral
    • 8.3.4. Others

9. By Distribution Channel

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.3. Market Attractiveness Index, By Distribution Channel Segment
    • 9.3.1. Hospitals Pharmacies*
      • 9.3.1.1. Introduction
      • 9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 9.3.2. Retail Pharmacies
    • 9.3.3. Online Pharmacies
    • 9.3.4. Others

10. By Region

  • 10.1. Introduction
  • 10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 10.3. Market Attractiveness Index, By Region
  • 10.4. North America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. U.S.
      • 10.4.6.2. Canada
      • 10.4.6.3. Mexico
  • 10.5. Europe
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. Germany
      • 10.5.6.2. U.K.
      • 10.5.6.3. France
      • 10.5.6.4. Italy
      • 10.5.6.5. Spain
      • 10.5.6.6. Rest of Europe
  • 10.6. South America
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.6.6.1. Brazil
      • 10.6.6.2. Argentina
      • 10.6.6.3. Rest of South America
  • 10.7. Asia Pacific
    • 10.7.1. Introduction
    • 10.7.2. Key Region-Specific Dynamics
    • 10.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.7.6.1. China
      • 10.7.6.2. India
      • 10.7.6.3. Japan
      • 10.7.6.4. Australia
      • 10.7.6.5. Rest of Asia Pacific
  • 10.8. Middle East and Africa
    • 10.8.1. Introduction
    • 10.8.2. Key Region-Specific Dynamics
    • 10.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Johnson & Johnson*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Merck & Co., Inc.
  • 12.3. Bayer AG
  • 12.4. Sanofi
  • 12.5. Pfizer
  • 12.6. F. Hoffmann-La Roche
  • 12.7. Allergan
  • 12.8. Valeant Pharmaceuticals
  • 12.9. Pharmaderm Pharmaceuticals
  • 12.10. Abbvie, Inc
  • 12.11. Almirall, S.A.
  • 12.12. Astellas Pharma, Inc
  • 12.13. Biofrontera AG
  • 12.14. Bristol-Myers Squibb
  • 12.15. Cipher Pharmaceuticals
  • 12.16. Dermira, Inc.
  • 12.17. Glaxosmithkline Plc
  • 12.18. Mylan N.V. (LIST NOT EXHAUSTIVE)

13. DataM Intelligence

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us